EPO “Follow-On” Products In Europe Need Two Clinical Efficacy Trials, EMEA Says
This article was originally published in The Pink Sheet Daily
Executive Summary
European Medicines Agency draft guidance on registration requirements for biosimilar epoetin products says efficacy studies should include a “maintenance phase” and a “titration phase.” The guidelines also call for clinical safety data from at least 300 patients.
You may also be interested in...
EMEA Product-By-Product Biosimilar Guidelines To Continue With Alfa Interferon
Additional product-level annexes to European biosimilar guidelines will be created as needed, German regulatory official Weise says.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: